The FDA has cleared PrecivityAD2, a blood test that identifies brain amyloid pathology in adults as young as 40 with cognitive decline symptoms. The test demonstrates 97.6% sensitivity and 93.1% specificity against PET imaging and cerebrospinal fluid analysis, with consistent accuracy across multiple comorbidities—removing a significant diagnostic bottleneck that previously required costly PET scans or invasive spinal taps.
Key Points
- Blood test identifies amyloid pathology with 97.6% sensitivity, 93.1% specificity
- First FDA-cleared test authorized for symptomatic adults starting at age 40
- Maintains accuracy across 12 chronic conditions, including hypertension and diabetes
Longevity Analysis
Early identification of amyloid accumulation before irreversible neurological damage shifts Alzheimer's from a late-stage diagnosis to a condition amenable to intervention during treatment-responsive windows. A non-invasive biomarker that performs reliably in patients with multiple age-related comorbidities addresses a critical gap in clinical practice: it enables physicians to decode cognitive decline signals accurately in the actual population they treat, not idealized trial cohorts. This precision extends the window for therapeutic intervention, where timing determines treatment efficacy.
Original published by Longevity.Technology, by Kyle Umipig.